並列摘要
In recurrent or persistent ovarian germ cell tumors, there is no standardized approach to the treatment of it. Resection of recurrent disease after long periods of remission is largely accepted to have a similar effect to primary cytoreductive surgery. Further platinum-based combination therapy is the best chance for salvage. Chemotherapy regimens use in literature of recurrent ovarian germ cell tumors vary widely and include the same regimens used in primary therapy and agents active against recurrent testicular germ cell cancers.
延伸閱讀
- 李耀泰、陳福民、柯天龍、鄭文雄、郭宗正（2007）。復發性子宮內膜癌之手術治療。中華民國婦癌醫學雜誌，(2007年2)，12-17。https://doi.org/10.7010/JGO.200710.0012
- 吳紋綺、顏厥全（2023）。難纏的生殖細胞瘤併體細胞轉化惡性腫瘤。臨床醫學月刊，91(2)，73-77。https://doi.org/10.6666/ClinMed.202302_91(2).0014
- 詹日全、黃穰基、潘超群、王仲祺、王景平、劉時安（2007）。口腔癌治療後影響局部復發之相關因素分析。台灣耳鼻喉頭頸外科雜誌，42(4)，115-127。https://doi.org/10.6286/2007.42.4.115
- Baba, Y., Fujii, M., Tokumaru, Y., & Kato, Y. (2012). Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. Journal of Oncology, 2012(), 861-869-089. https://doi.org/10.1155/2012/986725
- Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A. (2009). Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009(), 509-522. https://doi.org/10.1155/2009/567486